Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8
Folia Biologica · 2025
DOI: 10.14712/fb2025071030109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Folia Biologica, 2025. Verfasst von Li Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Tumor Suppressor Proteins, Drug Resistance, Neoplasm. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weifang Medical University, Weifang University of Science and Technology.
Abstract (Originalsprache)
Ovarian cancer remains one of the most lethal gynaecological malignancies, with paclitaxel resistance being a major therapeutic challenge that limits treatment efficacy and patient survival. We found that although the BARD1 level was not significantly altered in patients with ovarian cancer (OC), patients with higher BARD1 levels had increased survival time, suggesting that the down-regulation of BARD1 may be related to the paclitaxel sensitivity. Through examining the expression of BARD1 in tumour samples from paclitaxel responders and non-responders, we observed that the BARD1 level was significantly reduced in non-responders. CYP2C8 was up-regulated in non-responders. Also, the BARD1 level was negatively correlated with the level of CYP2C8. BARD1 over-expression in OC cells could repress the CYP2C8 expression, while knockdown of BARD1 could up-regulate CYP2C8 expression, which could be rescued by H2A-Ub. Results from gain and loss of functional experiments indicated that BARD1 functions as a tumour suppressor during paclitaxel treatment, and BARD1 down-regulation increased the IC50 of paclitaxel from 2.46 nM to 5.33 nM in SK-OV-3 cells and from 3.11 nM to 7.51 nM in CaoV-3 cells. We are the first to demonstrate that the down-regulation of BARD1 contributes to paclitaxel resistance via up-regulating CYP2C8 in patients with OC, which provides a potent target for clinical OC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
- Gynecology Department 1, Affiliated Hospital of Shandong Second Medical University, Weifang, China. shunfengvictory@126.com.
- Gynecology Department, Affiliated Hospital of Shandong Second Medical University, Fuyanshan District, Weifang, China.
Förderung
- Weifang Medical University
- Weifang University of Science and Technology
Zitieren
APA
Zhang, L., Pan, Z., Zhang, L., Liu, H., Li, Z., & Feng, S. (2025). Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8. Folia Biologica. https://doi.org/10.14712/fb2025071030109
Vancouver
Zhang L, Pan Z, Zhang L, Liu H, Li Z, Feng S. Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8. Folia Biologica. 2025. doi:10.14712/fb2025071030109
BibTeX
@article{Zhang2025,
author = {Zhang, Li and Pan, Zixuan and Zhang, Liqin and Liu, Hua and Li, Zonglan and Feng, Shuo},
title = {Dysregulated BARD1 Contributes to Paclitaxel Resistance in Ovarian Cancer via Up-regulating CYP2C8},
journal = {Folia Biologica},
year = {2025},
doi = {10.14712/fb2025071030109}
}
EUVIMED